Generic Products

The settlement also includes APP's agreement to dismiss its appeal of the August 2010 federal district court decision holding that MDCO's application for Hatch Waxman patent term extension of the Angiomax composition of...

NovaDel Pharma, Inc., a specialty pharmaceutical company, has terminated license agreement with Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc. ) and Par Pharmaceutical Companies, Inc., for Zensana. Talon is a biopharmaceutical company, while...

The Medicines Company (MDCO) has settled the lawsuits filed in the US district court for the district of Delaware relating to the Abbreviated New Drug Application (ANDA) filed by APP Pharmaceuticals, LLC (APP)...

NovaDel Pharma, Inc., a specialty pharmaceutical company, has terminated its license agreements with Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc. ) and Par Pharmaceutical Companies, Inc., for Zensana. Talon is a biopharmaceutical company,...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/ec4c56/the_outlook_for_ph) has announced the addition of the "The Outlook for Pharmaceuticals Worldwide" subscription to their offering. Original, Respected And Reliable Market Reports That Provide Critical Business Insights To...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/6a233b/world_generic_mark) has announced the addition of the "World Generic Markets" subscription to their offering. World Generic Markets is the business publication designed to keep executives and industry analysts...

AMITYVILLE, N.Y. -- Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that it has acquired marketing and distribution rights to a topical wound gel product from Glycobiosciences , Inc. The...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/42dee7/product_profiles) has announced the addition of the "Product Profiles: Asthma/COPD - Novel Combinations Edge Closer to Market" report to their offering. Despite a number of well-established therapies, the...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/a40950/market_and_product) has announced the addition of the "Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor" report to their offering. The industry is bracing...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/57b733/market_and_product) has announced the addition of the "Market and Product Forecasts: Depression - Agomelatine failure creates US market opportunity" report to their offering. New product launches across the...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/454d3a/product_profiles) has announced the addition of the "Product Profiles: Marketed Antibacterials - Increasing genericization and fragmentation shape a crowded market" report to their offering. In the last two...

EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed exclusively its Oxybutynin Gel 3% to Daewoong Pharmaceuticals Co. Ltd.,for marketing in South Korea. Antares will receive undisclosed...

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/1c9d50/impact_of_patent_e) has announced the addition of the "Impact of Patent Expiry on Global Generic Drugs Market - Trends, Opportunities and Challenges Post 2011 " report to their offering. Fueled...

NEW YORK -- Forest Laboratories, Inc. (NYSE: FRX), an international pharmaceutical manufacturer and marketer, today announced that reported earnings per share were $1.04 in the third quarter of fiscal 2012. Reported earnings per...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/e774ed/market_and_product) has announced the addition of the "Market and Product Forecast: Osteoporosis - Prolia and odanacatib to restore growth in the market" report to their offering. Despite major...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/8f5a37/dermatology_therap) has announced the addition of the "Dermatology Therapeutics Market to 2017 - Alopecia Market is Forecast to Decline Due to Patent Expiry of Finasteride in 2013 and...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/f1260a/musculoskeletal_di) has announced the addition of the "Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014" report to their...

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/a21943/pagets_disease_of) has announced the addition of GlobalData 's new report "Paget's Disease of Bone (PDB) Therapeutics - Pipeline Assessment and Market Forecasts to 2018" to their offering. PDB...

-Expects Record Adjusted EBITDA in the range of $85 million to $90 million- LAKE FOREST, Ill. -- Akorn, Inc. (NASDAQ:AKRX), a niche specialty pharmaceutical company, today provided full year 2012 financial guidance. The...